EKNL super low float play with key partners just announced is making way for a MAJOR breakout run and xtremepicks is on HIGH news alert that will definitely push prices to record levels.
Belize City, Belize -- (SBWIRE) -- 10/11/2012 -- Publishers of daily penny stock newsletter xtremepicks (http://www.xtremepicks.com) looks at EKO International (EKNL:Pinksheets)
Xtremepicks recently confirmed that the “active float” for EKNL is only 5.5 Million shares and in the hands of very strong investors not selling for anything less than our $1.25 target level.
With what EKNL has in store, insiders not selling a single share for less than dollar land, and institutional groups now looking at EKNL and it’s $1.25 price target, xtremepicks is definitely going to see many more members become millionaires.
Healthy pause and consolidations add strength to a bullish run, just as investors have seen last week when EKNL built support near $0.12 price level before breaking out to push to near record highs and where prices sits now.
With EKNL building another solid support level, it is primed for the next level breakout and with expected MAJOR update from the company will take prices to record levels and ‘blue skies’
There’s one thing for sure, EKNL will be the 2012 trophy winner and is already outshining our 2011 Trophy winner Fuse Science (DROP).
EKNL will be the biggest winner of 2012 hands down with $1.25 price target in sight
Is it because EKNL released monster news last week announcing “EKO with Dr. Ziemer’s NeuroVasc Medical Inc. and NCI, distributor of Neurometrix (NASDAQ:NURO)’s NC-Stat DPN check device are now available in 100 of WalMart-Canada stores.”?
Perry Mayer BSc, MB, Bch, BAO, CCFPOr Maybe it’s Dr. Paul Ziemer, world renowned for his expertise in the medical field joining the team at EKNL?
Well then, it has to be the first of many Clinics starting to treat patients with their FDA approved FREMS technology that will also be presented at the 13th annual Medical show in London this month.
Not to mention Dr. Ziemer teaming up with Dr. Snow of Neurometrix, a NASDAQ Listed company (NURO) for exclusive hands on demonstration of their testing unit?
No doubt, these are MONSTER updates that are turning a lot of heads, and institutional investors eying that $1.25 target level.
These updates already give EKNL HUGE valuation and potential…
…BUT, IT IS WHAT’S STILL TO BE UNLEASHED BY EKNL THAT WILL NOT ONLY BE MIND ‘BLOWING’ IT WILL PROPEL EKNL PRICES ’SKY HIGH’ AND INTO RECORD TERRITORY
When ever there's opportunities like today to scoop super cheap shares on any minor dips, take advantage of them and xtremepicks definitely did again today – the potential is too big to pass up.
About EKO International
EKO International Corp. is a holding company focused on growth through acquisition. Each acquisition must have substantial growth potential and is expected to add assets and/or cash-flow to the consolidated financial statements of the Company. The Company is willing to examine a variety of proposed target businesses and if interested, will negotiate terms and conditions of purchase favorable to itself.
About NeuroVasc Clinical Inc
NeuroVasc Clinical Inc. has brought a solution to the North American market place. The patented technology called FREMS is an FDA and Health Canada approved device that uses a patented electrical frequency and duty cycle to stimulate blood vessel re-growth and tissue regeneration in tissue that has compromised nerve and blood vessel function. The patient is treated 10 times once daily for 40 minutes and the effects on the tissue will last up to 18 month depending on the overall health of the patient. Thus this treatment becomes part of the maintenance of the lower limb for the diabetic patient as they age and will be a key player in the prevention of painful neuropathy and the development of dangerous wounds.
Keep your eyes peeled for the latest updates on our twitter page, facebook page, and our website at http://www.xtremepicks.com.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)